Form D · Biotechnology
EnteroBiotix LTD
Glasgow, X0 · CIK 0001946072
Offering snapshot reported Apr 9, 2026 · SEC filing
- Reported sold
- $5.34M Indefinite offering
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 9, 2026 | Initial | $5,341,593 | No comparison | 6 | SEC filing |
| Jul 25, 2025 | Initial | $1,389,676 | No comparison | 2 | SEC filing |
| Apr 9, 2024 | Initial | $1,262,000 | No comparison | 1 | SEC filing |
| Feb 2, 2024 | Initial | $2,565,225 | No comparison | 3 | SEC filing |
| Aug 14, 2023 | Initial | $6,706,941 | No comparison | 3 | SEC filing |
| Sep 14, 2022 | Initial | $11,234,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-579740
Issue is denominated in GBP. USD figure is based on an exchange rate of GBP 1 = USD 1.3401 on April 8, 2026.
Source: Form D, filed Apr 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Iain Baird | Director |
| Mark Bamforth | Director |
| James Barnes | Executive |
| Barnes James | Executive |
| David Lawrence | Director |
| Christopher Lea | Director, Executive |
| James Roger Mc Ilroy | Director, Executive |
| Strange Melissa | Executive |
| Felix Andy Awili Olale | Director |
| Elmar Josef Schnee | Director |
| Melissa Strange | Executive |
| Douglas Campbell Thomson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Phoenix House Strathclyde Business Park
Glasgow, X0, ML4 3NJ
Glasgow, X0, ML4 3NJ